What Clywedog Therapeutics does

Clywedog Therapeutics is a clinical-stage biopharmaceutical company headquartered at 8 The Green, Suite 8666, Dover, Delaware, developing first- and best-in-class small-molecule therapies for metabolic and autoimmune diseases. The company is advancing three differentiated, clinical-stage product candidates: Balomenib (CLY-101), an oral, reversible menin protein–protein interaction (PPI) inhibitor intended to restore pancreatic beta-cell function and promote insulin production in Type 1 and Type 2 diabetes; CLY-201, an oral small-molecule TYK2 inhibitor designed to block type I interferon and IL-12/23 signaling and protect beta-cells from autoimmune destruction in Type 1 diabetes; and VTP-1000, an antigen-specific tolerance immunotherapy for celiac disease built on the SNAP-Tolerance Immunotherapy platform, which would enter the portfolio through the pending Barinthus Biotherapeutics merger. Discovery is supported by a proprietary hybrid AI/ML drug discovery platform developed in conjunction with Expert Systems, integrating multi-target and multi-property optimization, predictive pharmacology, and biomarker strategies across chemical/biological modalities including oral protein degraders, molecular glues, protein-protein interaction inhibitors, covalent/reversible binders, and synthetic lethality dual inhibitors.

Clywedog is pre-revenue with no commercial products; its primary clinical asset Balomenib has entered a multicenter, international Phase 1b study in Type 2 diabetes with up to 60 participants dosed over a 28-day treatment period (centers activated December 2025). Pricing is undetermined and no commercial distribution channels exist today; the company's stated go-to-market posture is commercialization through specialty pharmaceutical channels upon regulatory approval, supplemented by clinical-trial-site operations for current development. The company has no disclosed product revenue and is funded by venture capital.

Clywedog was co-founded and seed-funded by OrbiMed Advisors and Torrey Pines Investment, with additional support from the Expert Systems hybrid AI/ML drug discovery accelerator. On September 30, 2025, the company entered a definitive all-stock merger agreement with Barinthus Biotherapeutics plc (NASDAQ: BRNS), expected to close in the first half of 2026, after which the combined company will be renamed Clywedog Therapeutics, Inc. and trade on NASDAQ under the ticker CLYD, with Barinthus shareholders owning approximately 34% and Clywedog stockholders approximately 66% on a fully diluted basis. Additional investment from TPAV, LLC is intended to extend the combined company's cash runway through 2027. Upon closing, OrbiMed venture partner Iain Dukes will transition from CEO of Clywedog to Executive Chairman of the combined company, and Barinthus Bio CEO Bill Enright will become CEO. The merger has attracted two law-firm investigations (Halper Sadeh LLC; Monteverde & Associates PC) regarding potential breaches of fiduciary duty and federal securities laws.

Name

Clywedog Therapeutics

Legal name

Clywedog Therapeutics, Inc.

Website

https://clywedogther.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Clywedog Therapeutics is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapies for diabetes and, post-merger, celiac disease, with three clinical-stage candidates targeting beta-cell regeneration and immune tolerance.

Ownership category

akta.pro rank

Headquarters

HQ city

Dover

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage company. Upon regulatory approval, the company expects to commercialize novel small-molecule therapeutics for diabetes and autoimmune diseases through specialty pharmaceutical distribution channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Clywedog Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic and autoimmune diseases. Its pipeline includes Balomenib (CLY-101), a menin PPI inhibitor for Type 1 and Type 2 diabetes; CLY-201, a TYK2 inhibitor for Type 1 diabetes; and VTP-1000, an antigen-specific tolerance immunotherapy for celiac disease. The company is pre-revenue and intends to commercialize these products through specialty pharmaceutical channels upon regulatory approval.

Product overview

Clywedog Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of three differentiated clinical-stage product candidates targeting metabolic and autoimmune diseases. The portfolio includes: (1) Balomenib (CLY-101), an oral menin inhibitor for type 1 and type 2 diabetes that promotes beta-cell regeneration; (2) CLY-201, a TYK2 inhibitor for type 1 diabetes targeting autoimmune destruction of beta-cells; and (3) VTP-1000, an antigen-specific tolerance immunotherapy for celiac disease. The company was co-founded by OrbiMed Advisors and Torrey Pines Investment, with additional support from Expert Systems hybrid AI/ML drug discovery accelerator, and is pursuing a merger with Barinthus Biotherapeutics expected to close in mid-2026.

Differentiator

Problem solved

Functional benefit

Products and services

• Balomenib (CLY-101) A best-in-class, oral, reversible menin protein-protein interaction (PPI) inhibitor being developed for the treatment of Type 2 diabetes and Type 1 diabetes. By blocking menin interactions, it stimulates regeneration of pancreatic islets and improves de novo insulin production.
• CLY-201 (TYK2 Inhibitor) A first-in-class, oral, small-molecule TYK2 inhibitor with an outstanding safety and tolerability profile, in clinical development for T1D prevention and early treatment. It targets T-cell-mediated inflammation that destroys insulin-secreting pancreatic beta cells by mediating type I interferon and interleukin signaling.
• VTP-1000 A highly differentiated antigen-specific tolerance immunotherapy designed to prevent or reduce symptoms following gluten exposure in patients with celiac disease, utilizing the SNAP-Tolerance Immunotherapy (SNAP-TI) platform.

Quantifiable outcome

• Phase 1 completed with demonstrated safety and tolerability in healthy volunteers with PK/PD data supporting T1D and T2D potential
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

Two partnerships are on record, tiered supporting.

• ChemDivsupportingStrategic or Co-development Partner · 24 October 2025ChemDiv continues providing R&D services support for Clywedog Therapeutics following the merger announcement with Barinthus Biotherapeutics. ChemDiv is a contract research organization supporting ongoing research activities.
• Expert SystemssupportingStrategic or Co-development PartnerExpert Systems is a hybrid AI/ML drug discovery and development accelerator that provided additional support for Clywedog Therapeutics' formation. The company utilizes Expert Systems' hybrid AI/ML platform in its drug discovery approach.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• vTv Therapeutics: Clinical-stage small-molecule developer focused on metabolic and inflammatory diseases including diabetes. Closely comparable to Clywedog in stage (Phase 1/2), modality (oral small molecules), and therapeutic-area focus.
• Provention Bio (a Sanofi company): Developed TZIELD (teplizumab), the first disease-modifying therapy for T1D. Direct peer given Clywedog's T1D focus via CLY-201 (TYK2) and Balomenib beta-cell regeneration approach.
• Lexicon Pharmaceuticals: Small-molecule developer with diabetes programs (sotagliflozin for T1D/T2D, LX9211). Comparable stage, modality, and metabolic-disease focus.
• MannKind Corporation: Diabetes-focused therapeutics company (Afrezza inhaled insulin, V-Go). Comparable patient population and clinical-stage-to-commercial company focused exclusively on metabolic disease.
• DiaMedica Therapeutics: Clinical-stage developer of recombinant and small-molecule therapies for diabetes and kidney disease. Comparable stage, modality mix, and metabolic-disease orientation.
• Oramed Pharmaceuticals: Clinical-stage developer of oral protein-based therapies for diabetes (oral insulin, ORMD-0801). Directly comparable on disease-modifying oral approaches for T1D/T2D.
• Terns Pharmaceuticals: Clinical-stage small-molecule developer focused on metabolic diseases (obesity, NASH/MASH) with oral therapies. Comparable stage, modality, and metabolic-disease focus.
• Kezar Life Sciences: Clinical-stage small-molecule developer for autoimmune diseases (lupus, autoimmune hepatitis). Comparable stage, modality, and autoimmune therapeutic-area focus relevant to Clywedog's CLY-201 (TYK2) program.

Broad incumbents

• Vertex Pharmaceuticals: Pursuing a curative T1D cell therapy (VX-880/zimislecel) at significantly greater scale and capitalization. Comparable on T1D therapeutic area but a much larger, broad-portfolio incumbent.

Emerging players

• Inversago Pharma: Pre-commercial developer of peripherally-acting CB1 inverse agonists for obesity and metabolic disorders; acquired by Novo Nordisk in 2023. Comparable emerging metabolic-disease player taken out by large pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ClywedogTher

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clywedog Therapeutics